Biological
CM336 Injection
CM336 Injection is a biological therapy with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_3
1
25%
Ph phase_1
2
50%
Ph phase_2
1
25%
Phase Distribution
2
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting3
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
Trials by Status
not_yet_recruiting125%
recruiting375%
Recent Activity
3 active trials
Showing 4 of 4
recruitingphase_1
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
NCT07175493
not_yet_recruitingphase_3
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
NCT07181239
recruitingphase_1
A Study to Evaluate CM336 in Adults with Autoimmune Bullous Disease
NCT06900010
recruitingphase_2
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
NCT06799611
Clinical Trials (4)
Showing 4 of 4 trials
NCT07175493Phase 1
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
NCT07181239Phase 3
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
NCT06900010Phase 1
A Study to Evaluate CM336 in Adults with Autoimmune Bullous Disease
NCT06799611Phase 2
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4